Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.

While one clinical study demonstrated a modestly significant effect on 6MWD and dypsnoea of oral treprostinil as monotherapy when compared with placebo [ 47 ], other studies failed to show an effect with adding oral treprostinil in patients receiving stable background therapy with an ERA and/or a PDE-5i [ 48 , 49 ].

also in 257 other papers